Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
Editor Note: For more information about this release, please scroll to bottom
LONDON, May 14, 2014 /PRNewswire/ --
The US markets saw a mixed sentiment on Tuesday, May 13, 2014, with the NASDAQ Composite closing at 4,130.17, down 0.33%, the Dow Jones Industrial Average ending the session at 16,715.44, up 0.12% and the S&P 500 edging 0.04% higher to finish the trading session at 1,897.45. The session saw a positive impact from Energy, Industrials and Consumer Staples sectors along with a drag from Financials, Consumer Discretionary and Telecommunication Services sectors. A number of stocks saw large movements, including Halozyme Therapeutics Inc. (NASDAQ: HALO), Goodrich Petroleum Corporation (NYSE: GDP), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) and Coronado Biosciences Inc. (NASDAQ: CNDO). Free technical research on HALO, GDP, BCRX and CNDO can be downloaded upon signing up at:
Halozyme Therapeutics Inc.'s stock finished Tuesday's session 6.91% higher at $8.04. A total of 11.65 million shares were traded, which was much above its three months average volume of 2.22 million shares. The stock moved between $7.98 and $9.38 during the session. Over the past three trading sessions and last one month, Halozyme Therapeutics Inc.'s shares have surged 13.40% and 8.36%, respectively. However, from the year's start, the company's stock has declined 46.36%.The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $11.73 is greater than its 50-day moving average of $10.31. Halozyme Therapeutics Inc.'s stock has a Relative Strength Index (RSI) of 35.81. On May 12, 2014, Halozyme Therapeutics Inc. announced its Q1 2014 financial results with net loss of $26.5 million, or $0.22 per diluted share. Sign up today to read free research on HALO at:
On Tuesday, Goodrich Petroleum Corp.'s stock fluctuated between $23.45 and $24.36 before ending the session 4.92% higher at $24.11. Goodrich Petroleum Corp.'s stock reported a trading volume of 1.44 million shares, below its three months average volume of 2.37 million shares. Goodrich Petroleum Corp.'s shares have rallied 31.03% in the last one month and 34.02% in the previous three months. Also, from the beginning of 2014, the company's stock has advanced 41.66%. The S&P 500 Energy Sector Index registered a gain of 0.32% during the session, and it has charted up 6.63% in the last one month. The stock is trading above its 50-day and 200-day moving averages of $19.02 and $20.01, respectively. Moreover, shares of the company have an RSI of 53.68. Sign up today to read free research on GDP at:
BioCryst Pharmaceuticals Inc.'s stock surged 8.04% on Tuesday, closing the day at $8.33. The stock recorded a trading volume of 1.24 million shares, above its three months average volume of 0.96 million shares. The stock oscillated between $7.60 and $8.49 during the trading session. Over the previous three trading sessions and since the start of this year, BioCryst Pharmaceuticals Inc.'s shares have gained 13.03% and 9.61%, respectively. However, the stock has lost 6.51% in the last one month. The S&P 500 Health Care Sector Index reported a gain of 0.16% during the trading session and it has charted up 1.79% in the past three trading sessions. The stock is trading above its 200-day moving average. The stock's 50-day moving average of $9.76 is above its 200-day moving average of $7.96. Additionally, the stock has an RSI of 39.62. Sign up today to read free research on BCRX at:
On Tuesday, shares in Coronado Biosciences Inc. recorded a trading volume of 0.45 million shares, lower than its three months average volume of 0.56 million shares. The stock ended the day at an intra-day high of $1.77, which was 10.63% above its previous day's closing price of $1.60. Coronado Biosciences Inc.'s shares have advanced 13.46% in the past three trading sessions and 0.57% in the last one month. However, the stock has fallen by 32.70% since the start of this year. The S&P 500 Health Care Sector Index mapped a gain of 0.16% during the session, and the index has charted up 0.84% in the last three months. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $3.75 is above its 50-day moving average of $2.01. Furthermore, shares of the company have an RSI of 32.49. Sign up today to read free research on CNDO at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.